Daiichi Sankyo Company, Limited is a Japan-based holding company mainly engaged in the manufacturing and sale of pharmaceuticals. The Company has two business segments. The Pharmaceuticals segment is involved in the research, development, manufacturing and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical making. The Others segment is involved in the real estate leasing, the insurance agency business, as well as the provision of human affairs and accounting services.

Pharming Group N.V. is a Netherlands-based biotechnology company. The Company has facilities both in the Netherlands and the United States. Pharming develops products for the treatment of diseases with significant medical needs, including genetic disorders, diseases associated with the immune system, ageing diseases, and nutritional products. The Company’s technologies include platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of DNA repair via its subsidiary DNage BV. Pharming products under development are divided into three categories: biopharmaceuticals, biomaterials, and bio-nutritionals. Products in the most advanced stage of development and closest to commercialization are Rhucin and human lactoferrin for use in food products. Pharming has several partnerships and collaborations with, inter alia, AgResearch, US Army, Aslan and Schering-Plough.

Since its inception in 1740, Whatman knows what it takes to separate the wheat from the chaff. Whatman company makes filters, membranes, and specialty products for applications in the analytical, health care, and bioscience markets in some 70 countries. Whatman company's products can be found in medical devices and diagnostic testing kits. Whatman has also developed technology for the isolation, transportation, storage, and purification of DNA for gathering genetic information. Whatman makes other products such as blotting papers, syringe filters, and chromatography products. Whatman company was acquired by GE Healthcare in 2008.

Dyax Corp. was founded in 1989 and is headquartered in Cambridge, Massachusetts. Dyax Corp. (Dyax) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company uses the drug discovery technology, known as phage display, to identify antibody, small protein and peptide compounds for clinical development. The Company’s product DX-88 (ecallantide), is in late stage clinical trial development in two separate indications. In addition to DX-88, the phage display technology has allowed Dyax to develop a substantial pipeline of drug candidates. In June 2008, the Company completed a second phase three study, known as EDEMA4.

Heska Corporation develops, manufactures, markets, sells, and supports veterinary products for the canine and feline companion animal health markets. It operates in two segments, Core Companion Animal Health; and Other Vaccines, Pharmaceuticals, and Products. The Core Companion Animal Health segment offers veterinary diagnostic and other instruments, including handheld blood analyzers, veterinary chemistry analyzers, veterinary hematology analyzers, IV pumps, and consumable supplies; point-of-care diagnostic and other tests, such as heartworm diagnostic tests for dogs and cats, and early renal damage detection products; and veterinary diagnostic laboratory products and services, which comprise allergy diagnostic products and services, as well as ERD Reagent Packs used to detect microalbuminuria. It provides pharmaceuticals and supplements, such as heartworm prevention products, nutritional supplements, and hypothyroid treatment products; and vaccines and other biologicals for the treatment of allergies and feline respiratory diseases.This segment sells its products to veterinarians directly, as well as through telephone sales force, independent third party distributors, and other distribution relationships. The Other Vaccines, Pharmaceuticals, and Products segment provides private label vaccines and pharmaceuticals primarily for cattle, as well as for other animals, including small mammals and fish. It offers bovine vaccines, and biological and pharmaceutical products for other animal health companies, as well as provides turnkey services, which consist of research, licensing, production, labeling, and packaging of products, as well as validation support and distribution services. This segment sells its products through third parties under third party labels. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.

DRAXIS Specialty Pharmaceuticals (formerly DRAXIS Health) lights up your insides with its own radiopharmaceuticals, but its main business is making other drug companies' injectable drugs, lotions and pills. The company's larger DRAXIS Pharma unit is a contract manufacturer specializing in liquid and freeze-dried injectable drugs, though it also makes sterile and non-sterile ointments, creams, and other formulations. Another unit, DRAXIMAGE, develops and makes radiopharmaceuticals, such as radioactive iodine, for use in diagnostic and therapeutic nuclear medicine procedures. DRAXIMAGE sells its products mostly in the US and Canada. In 2008 India-based Jubilant Organosys acquired DRAXIS for about $255 million.

Novartis Pharmaceuticals holds down the fort on this side of the big pond. As the US pharmaceuticals marketing affiliate of Swiss drug giant Novartis AG, the company helps with the development and sales of its parent company's products in the US. Its product line addresses a range of ailments including cardiovascular and respiratory diseases, gastrointestinal complaints, central nervous system disorders, cancer and blood disorders, bone and joint conditions, and organ transplants. Key products include tumor growth inhibitor Gleevec, high blood pressure drug Diovan, and attention deficit disorder therapies Focalin and Ritalin.

Sucampo Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland. Sucampo Pharmaceuticals, Inc., through its subsidiaries, focuses on the discovery, development, and commercialization of drugs based on prostones in the United States, Europe, and Japan. It offers prostone-based compounds for the treatment of gastrointestinal, vascular, respiratory, and central nervous system diseases and disorders. The company primarily markets Amitiza for the treatment of chronic idiopathic constipation in adults, as well as for irritable bowel syndrome with constipation in adult women. It also offers Rescula (unoprostone isopropyl) for the treatment of glaucoma. In addition, Sucampo Pharmaceuticals is conducting two Phase III pivotal trials of Amitiza for opioid-induced bowel dysfunction; a Phase II proof of concept trial of Cobiprostone for the prevention of non-steroidal anti-inflammatory drug induced ulcers; various preclinical trials of Cobiprostone for cystic fibrosis respiratory symptoms, topical ulcers and wounds, and chronic obstructive pulmonary disease; and a preclinical phase study of SPI-017 for Alzheimer's disease. The company also has various pre-clinical studies of six additional preclinical prostone compounds, including two combination candidates for age-related diseases.

FAES was founded in 1933. Faes Farma SA is a Spanish company primarily engaged in the research, manufacture and commercialization of pharmaceutical products, such as prescription drugs, over-the-counter medicines and skin-care treatments, as well as raw materials used in the pharmaceutical industry. The Company’s facilities include one research and development center and three manufacturing plants, which are located in the cities of Leioa, Lisbon and Madrid. The Company is a parent of Grupo Faes, a group which comprises Laboratorios Vitoria SA, Laboratorios Veris SA, Iquinosa Farma SA, Lazlo International SA, Hispana Dos SA SICAV, Ingaso Farm SLU, Biotecnet I MAS D SA, Esfion SA, Olve Farmaceutica Lda, Veris Farmaceutica Lda, Vitalion Lda and Farmalavi Lda. Through its subsidiaries, the Company operates mainly in Spain and Portugal. It also has presence in approximately 50 countries in Europe, America, Africa and Asia.

Obagi Medical Products, Inc. company was founded in 1988 and is headquartered in Long Beach, California. Obagi Medical Products, Inc. is a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets. The Company develops and commercializes prescription-based products, topical skin health systems that enable physicians to treat a range of skin conditions, including pre-mature aging, photo-damage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, rosacea and soft tissue deficits, such as fine lines and wrinkles. The Company markets and sells a range of systems and related products for the enhancement of skin health. Its principal product line is its Obagi Nu-Derm System. Its Obagi Nu-Derm System is a prescription-based topical skin health system that enhances the skin's overall health by correcting photo damage using drugs that, by definition, work at the cellular level, resulting in a reduction of the visible signs of aging. In January 2009, the Company launched the Obagi Rosaclear System.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.